Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
NCT ID: NCT00971308
Last Updated: 2011-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
37 participants
INTERVENTIONAL
2009-10-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
NCT00722358
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
NCT00663208
Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients
NCT01525212
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
NCT00664625
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
NCT01012895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS-824393 (Panel 1)
BMS-824393
Capsule, Oral, 50mg, Once Daily, 3 days
BMS-824393 (Panel 2)
BMS-824393
Capsule, Oral, 100mg, Once Daily, 3 days
BMS-824393 (Panel 3)
BMS-824393
Capsule, Oral, 10mg, Once Daily, 3 days
BMS-824393 (Panel 4)
BMS-824393
Capsule. Oral, 1mg, Once Daily, 3 days
BMS-824393 (Panel 5)
BMS-824393
Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-824393
Capsule, Oral, 50mg, Once Daily, 3 days
BMS-824393
Capsule, Oral, 100mg, Once Daily, 3 days
BMS-824393
Capsule, Oral, 10mg, Once Daily, 3 days
BMS-824393
Capsule. Oral, 1mg, Once Daily, 3 days
BMS-824393
Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HCV RNA viral load of ≤10\*5\* IU/mL (100,000 IU/mL)
* Body Mass Index (BMI) of 18 to 35 kg/m², inclusive
Exclusion Criteria
* Any significant acute or chronic medical illness which is not stable or is not controlled with medication or is not consistent with Hepatitis C infection
* Any other medical, psychiatric and/or social reason which, in the opinion of the Investigator, would make the candidate inappropriate for participation in this study
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Clinical Research Institute
Anaheim, California, United States
West Coast Clinical Trials, Llc
Cypress, California, United States
Elite Research Institute
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Parexel International - Baltimore Epcu
Baltimore, Maryland, United States
Alamo Medical Research
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI451-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.